| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.056 | 0.3 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.036 | 0.5 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.037 | 0.5 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | 0.033 | 0.5 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.016 | 0.8 |